The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42: A Cross-Validation Study Against Amyloid Positron Emission Tomography
Abstract
IMPORTANCE: Before adding cerebrospinal fluid (CSF) biomarkers to the diagnostic workup of Alzheimer disease, it needs to be determined whether CSF biomarkers analyzed in routine clinical practice can reliably predict cortical β-amyloid (Aβ) deposition. OBJECTIVES: To study whether CSF biomarkers, analyzed consecutively in routine clinical practice during 2 years, can predict cortical Aβ deposition and to establish a threshold for Aβ42 abnormality. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study (The Swedish BioFINDER [Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably] Study) was conducted at 3 memory clinics. It involved consecutively referred, nondemented patients with mild cognitive symptoms (original cohort, n = 118; validation cohort, n = 38). EXPOSURES: Amyloid positron emission tomography imaging with 18F-flutemetamol. MAIN OUTCOMES AND MEASURES: Analyses of CSF Aβ42, total tau, and phosphorylated tau using an enzyme-linked immunosorbent assay (INNOTEST) in clinical samples. RESULTS: The agreement between Aβ classification with CSF Aβ42 and 18F-flutemetamol positron emission tomography was very high (κ = 0.85). Of all the cases, 92% were classified identically using an Aβ42 cutoff of 647 pg/mL or less. Cerebrospinal fluid Aβ42 predicted abnormal cortical Aβ deposition accurately (odds ratio, 165; 95% CI, 39-693; area under the receiver operating characteristic curve, 0.94; 95% CI, 0.88-0.97). The association was independent of age, sex, APOE (apolipoprotein E) genotype, hippocampal volume, memory, and global cognition (adjusted odds ratio, 169; 95% CI, 25-1143). Using ratios of CSF Aβ42:tau or Aβ42:phosphorylated tau did not improve the prediction of Aβ deposition. Cerebrospinal fluid Aβ42 correlated significantly with Aβ deposition in all cortical regions. The highest correlations were in regions with high 18F-flutemetamol retention (eg, posterior cingulum and precuneus, r = -0.72). 18F-flutemetamol retention, but not CSF Aβ42, correlated significantly with global cognition (r = -0.32), memory function (r = -0.28), and hippocampal volume (r = -0.36) among those with abnormal Aβ deposition. Finally, the CSF Aβ42 cutoff derived from the original cohort (≤647 pg/mL) had an equally high agreement (95%; κ = 0.89) with 18F-flutemetamol positron emission tomography in the validation cohort. CONCLUSIONS AND RELEVANCE: Cerebrospinal fluid Aβ42 analyzed consecutively in routine clinical practice at an accredited laboratory can be used with high accuracy to determine whether a patient has normal or increased cortical Aβ deposition and so can be valuable for the early diagnosis of Alzheimer disease. Abnormal 18F-flutemetamol retention levels correlate with disease stage in patients with mild cognitive symptoms, but this is not the case for CSF Aβ42 measurements.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mixture modeling statistics provide an unbiased threshold for abnormality (i.e., the diagnosis or status is not used in analysis) and it is a well-established method for defining Aβ PET cut-offs12, 17, 60, 61.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [60]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Practical Statistics for Medical Research.
Walter, S., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,666
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
Measuring agreement in method comparison studies
Bland, J. M., & Altman, D. G. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800204 · Cited by 9,619
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationPassing, H., & Bablok, W. (1983) · cclm · doi:10.1515/cclm.1983.21.11.709 · Cited by 1,513
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 368
Cullen, N. C., Janelidze, S., Mattsson, N., Palmqvist, S., Bittner, T., Suridjan, I., Jethwa, A., Kollmorgen, G., Brum, W. S., Zetterberg, H., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12706 · Cited by 85
Self-citationPannee, J., Portelius, E., Minthon, L., Gobom, J., Andréasson, U., Zetterberg, H., Hansson, O., & Blennow, K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13838 · Cited by 84
Self-citationBorland, E., Edgar, C., Stomrud, E., Cullen, N., Hansson, O., & Palmqvist, S. (2022) · Neurology · doi:10.1212/wnl.0000000000200817 · Cited by 83
Self-citationHoscheidt, S. M., Starks, E. J., Oh, J. M., Zetterberg, H., Blennow, K., Krause, R. A., Gleason, C. E., Puglielli, L., Atwood, C., Carlsson, C. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160110 · Cited by 84
Self-citationChételat, G., Ossenkoppele, R., Villemagne, V. L., Perrotin, A., Landeau, B., Mézenge, F., Jagust, W. J., Dore, V., Miller, B. L., Egret, S., et al. (2016) · Brain · doi:10.1093/brain/aww159 · Cited by 80
Starks, E. J., O’Grady, J. P., Hoscheidt, S. M., Racine, A. M., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Puglielli, L., Asthana, S., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150072 · Cited by 82
Self-citationCSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults
Idland, A., Sala‐Llonch, R., Borza, T., Watne, L. O., Wyller, T. B., Brækhus, A., Zetterberg, H., Blennow, K., Walhovd, K. B., & Fjell, A. M. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.09.012 · Cited by 76
Self-citationLi, Q., Villemagne, V. L., Doecke, J. D., Rembach, A., Sarros, S., Varghese, S., McGlade, A. R., Laughton, K. M., Pertile, K. K., Fowler, C. J., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150247 · Cited by 75
Gooblar, J., Roe, C. M., Selsor, N. J., Gabel, M. J., & Morris, J. C. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.2875 · Cited by 78
18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
Smith, R. A., Schöll, M., Londos, E., Ohlsson, T. G., & Hansson, O. (2018) · Scientific Reports · doi:10.1038/s41598-018-23041-x · Cited by 76
Self-citationPreclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
Höglund, K., Kern, S., Zettergren, A., Börjesson‐Hanson, A., Zetterberg, H., Skoog, I. G., & Blennow, K. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.252 · Cited by 74
Self-citationP‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
Campbell, M. R., Ashrafzadeh‐Kian, S., Petersen, R. C., Mielke, M. M., Syrjanen, J. A., van Harten, A. C., Lowe, V. J., Jack, C. R., Bornhorst, J. A., & Algeciras‐Schimnich, A. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12190 · Cited by 79
Villemagne, V. L., Rowe, C. C., Barnham, K. J., Cherny, R. A., Woodward, M., Bozinosvski, S., Salvado, O., Bourgeat, P., Perez, K. A., Fowler, C. J., et al. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.001 · Cited by 73
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Mattsson, N., Palmqvist, S., Blennow, K., & Hansson, O. (2020) · Nature Communications · doi:10.1038/s41467-020-19957-6 · Cited by 70
Self-citationStaging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study
Chen, S.-D., Lu, J.-Y., Li, H.-Q., Yang, Y.-X., Jiang, J.-H., Cui, M., Zuo, C.-T., Tan, L., Dong, Q., Yu, J.-T., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01602-5 · Cited by 71
Ossenkoppele, R., Mattsson, N., Teunissen, C. E., Barkhof, F., Pijnenburg, Y. A. L., Scheltens, P., van der Flier, W. M., & Rabinovici, G. D. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.011 · Cited by 76
(ADNI), T. A. D. N. I., Bouallègue, F. B., Mariano‐Goulart, D., & Payoux, P. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0260-z · Cited by 73
Zeng, X., Chen, Y., Sehrawat, A., Lee, J., Lafferty, T. K., Kofler, J., Berman, S., Sweet, R. A., Tudorascu, D., Klunk, W. E., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00711-1 · Cited by 79
Self-citationKLOTHO heterozygosity attenuates APOE4 -related amyloid burden in preclinical AD
Erickson, C. M., Schultz, S. A., Oh, J. M., Darst, B. F., Ma, Y., Norton, D., Betthauser, T., Gallagher, C. L., Carlsson, C. M., Bendlin, B. B., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007323 · Cited by 70
Self-citationLeuzy, A., Ashton, N. J., Mattsson, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Nordberg, A. K., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 73
Self-citationJohansson, M., Stomrud, E., Johansson, P., Svenningsson, A., Palmqvist, S., Janelidze, S., van Westen, D., Mattsson, N., & Hansson, O. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.01.012 · Cited by 77
Self-citationKoychev, I. G., on behalf of the Deep and Frequent Phenotyping study team (http://www.dementiastudy.co.uk/), Gunn, R. N., Firouzian, A., Lawson, J., Zamboni, G., Ridha, B. H., Sahakian, B. J., Rowe, J. B., Thomas, A. J., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170129 · Cited by 67
Self-citationFantoni, E. R., Chalkidou, A., O’ Brien, J. T., Farrar, G., & Hammers, A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171093 · Cited by 68
Use of amyloid-PET to determine cutpoints for CSF markers
Zwan, M. D., Rinne, J. O., Hasselbalch, S. G., Nordberg, A. K., Lleó, A., Herukka, S., Soininen, H. S., Law, I. G., Bahl, J. M. C., Carter, S. F., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002081 · Cited by 66
The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview
Jefferson, A. L., Gifford, K. A., Acosta, L. M. Y., Bell, S. P., Donahue, M. J., Davis, L. T., Gottlieb, J., Gupta, D. K., Hohman, T. J., Lane, E., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150914 · Cited by 68
Self-citationKang, J. H., Korecka, M., Lee, E. B., Cousins, K. A. Q., Tropea, T. F., Chen-Plotkin, A. A., Irwin, D. J., Wolk, D., Brylska, M., Wan, Y., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad139 · Cited by 64
Neurofilament relates to white matter microstructure in older adults
Moore, E. E., Hohman, T. J., Badami, F. S., Pechman, K. R., Osborn, K. E., Acosta, L. M. Y., Bell, S. P., Babicz, M. A., Gifford, K. A., Anderson, A. W., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.023 · Cited by 65
Self-citationPalmqvist, S., Insel, P. S., Zetterberg, H., Blennow, K., Brix, B., Stomrud, E., Initiative, T. A. D. N., study, T. S. B., Mattsson, N., & Hansson, O. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.014 · Cited by 65
Self-citationLiebsch, F., Kulic, L., Teunissen, C., Shobo, A., Ulku, I., Engelschalt, V., Hancock, M. A., van der Flier, W. M., Kunach, P., Rosa-Neto, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10152-w · Cited by 68
Guo, T., Korman, D., Joie, R. L., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00665-8 · Cited by 67
Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition
Schultz, S. A., Boots, E. A., Almeida, R. P., Oh, J. M., Einerson, J. A., Korcarz, C. E., Edwards, D. F., Koscik, R. L., Dowling, N. M., Gallagher, C. L., et al. (2015) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617715000843 · Cited by 65
Self-citationGertje, E. C., Janelidze, S., van Westen, D., Cullen, N. C., Stomrud, E., Palmqvist, S., Hansson, O., & Mattsson, N. (2023) · Neurology · doi:10.1212/wnl.0000000000207113 · Cited by 62
Self-citationKarlsson, L., Vogel, J. W., Arvidsson, I., Åström, K., Janelidze, S., Blennow, K., Palmqvist, S., Stomrud, E., Mattsson, N., & Hansson, O. (2024) · Nature Communications · doi:10.1038/s41467-024-47971-5 · Cited by 62
Self-citationBiomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 70
Hahn, A., Strandberg, T. O., Stomrud, E., Nilsson, M., van Westen, D., Palmqvist, S., Ossenkoppele, R., & Hansson, O. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz020 · Cited by 61
Self-citationClinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis
Leuzy, A., Savitcheva, I., Chiotis, K., Lilja, J., Andersen, P., Bogdanović, N., Jelić, V., & Nordberg, A. K. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04297-5 · Cited by 60
Spread of pathological tau proteins through communicating neurons in human Alzheimer’s diseasePreprint
Vogel, J. W., Iturria‐Medina, Y., Strandberg, O. T., Smith, R. A., Evans, A. C., Hansson, O., & for the Alzheimer’s Disease Neuroimaging Initiative, A. T. S. B. S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/555821 · Cited by 64
Self-citationHeurling, K., Leuzy, A., Zimmer, E. R., Lubberink, M., & Nordberg, A. K. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3208-1 · Cited by 59
Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
Mattsson, N., Insel, P. S., Palmqvist, S., Stomrud, E., van Westen, D., Minthon, L., Zetterberg, H., Blennow, K., & Hansson, O. (2016) · Nature Communications · doi:10.1038/ncomms10918 · Cited by 60
Self-citationBjerke, M., Andréasson, U., Kuhlmann, J., Portelius, E., Pannee, J., Lewczuk, P., Umek, R. M., Vanmechelen, E., Vanderstichele, H., Stoops, E., et al. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0733 · Cited by 56
Self-citationMinta, K., Brinkmalm, G., Janelidze, S., Sjödin, S., Portelius, E., Stomrud, E., Zetterberg, H., Blennow, K., Hansson, O., & Andréasson, U. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00585-7 · Cited by 57
Self-citationPaterson, R. W., Toombs, J., Slattery, C. F., Nicholas, J. M., Andréasson, U., Magdalinou, N. K., Blennow, K., Warren, J. D., Mummery, C. J., Rossor, M. N., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7904-3 · Cited by 57
Self-citationBlennow, K., Biscetti, L., Eusebi, P., & Parnetti, L. (2016) · Movement Disorders · doi:10.1002/mds.26656 · Cited by 61
Self-citationSchedin‐Weiss, S., Gaunitz, S., Sui, P., Chen, Q., Haslam, S. M., Blennow, K., Winblad, B. G., Dell, A., & Tjernberg, L. O. (2019) · FEBS Journal · doi:10.1111/febs.15197 · Cited by 55
Self-citationMoore, E. E., Liu, D., Li, J., Schimmel, S. J., Cambronero, F. E., Terry, J. G., Nair, S., Pechman, K. R., Moore, M. E., Bell, S. P., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012257 · Cited by 56
Self-citationAssociation of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition
Tideman, P., Stomrud, E., Leuzy, A., Mattsson, N., Palmqvist, S., Hansson, O., & Initiative, A. D. N. (2022) · Neurology · doi:10.1212/wnl.0000000000013299 · Cited by 54
Self-citationEffect of Fear of Falling on Turning Performance in Parkinson’s Disease in the Lab and at Home
Haertner, L., Elshehabi, M., Zaunbrecher, L., Pham, M. H., Maetzler, C., van Uem, J. M. T., Hobert, M. A., Hucker, S., Nussbaum, S., Berg, D., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00078 · Cited by 55
Ding, M., Ding, S., Du, D., Wang, X., Hu, X., Guan, P., Lyu, Z., & Lin, Y. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117087 · Cited by 54
Clinical significance of fluid biomarkers in Alzheimer’s Disease
Lewczuk, P., Łukaszewicz‐Zając, M., Mroczko, P., & Kornhuber, J. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00107-0 · Cited by 56
Cicognola, C., Mattsson, N., van Westen, D., Zetterberg, H., Blennow, K., Palmqvist, S., Ahmadi, K., Strandberg, O. T., Stomrud, E., Janelidze, S., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207358 · Cited by 56
Self-citationGroot, C., Smith, R. A., Stomrud, E., Binette, A. P., Leuzy, A., Wuestefeld, A., Wisse, L. E. M., Palmqvist, S., Mattsson, N., Janelidze, S., et al. (2022) · Brain · doi:10.1093/brain/awac329 · Cited by 53
Self-citationCerebrospinal fluid β-amyloid42 and neurofilament light relate to white matter hyperintensities
Osborn, K. E., Liu, D., Samuels, L. R., Moore, E. E., Cambronero, F. E., Acosta, L. M. Y., Bell, S. P., Babicz, M. A., Gordon, E. A., Pechman, K. R., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.03.028 · Cited by 51
Self-citationAssociation of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults
Guo, T., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000010596 · Cited by 51
Obrocki, P., Khatun, A., Ness, D., Senkevich, K. A., Hanrieder, J., Capraro, F., Mattsson, N., Andréasson, U., Portelius, E., Ashton, N. J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00586-6 · Cited by 51
Self-citationCarswell, C. J., Win, Z., Muckle, K., Kennedy, A. M., Waldman, A. D., Dawe, G., Barwick, T. D., Khan, S., Malhotra, P., & Perry, R. J. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316194 · Cited by 50
Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease
Adamczuk, K., Schaeverbeke, J. M., Vanderstichele, H., Lilja, J., Nelissen, N., Laere, K. V., Dupont, P. J., Hilven, K., Poesen, K., & Vandenberghe, R. R. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0159-5 · Cited by 49
Bensaïdane, M. R., Beauregard, J., Poulin, S. P., Buteau, F.-A., Guimond, J. V., Bergeron, D., Verret, L., Fortin, M., Houde, M., Bouchard, R. W., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151180 · Cited by 50
Rodríguez‐Ayllón, M., Solis‐Urra, P., Arroyo‐Avila, C., Álvarez-Ortega, M., Molina‐García, P., Molina‐Hidalgo, C., Gómez-Río, M., Brown, B. M., Erickson, K. I., & Esteban‐Cornejo, I. (2023) · Journal of sport and health science/Journal of Sport and Health Science · doi:10.1016/j.jshs.2023.08.001 · Cited by 50
Blennow, K., & Zetterberg, H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.006 · Cited by 46
Self-citationMüller, E. G., Edwin, T. H., Stokke, C., Navelsaker, S. S., Babovic, A., Bogdanović, N., Knapskog, A., & Revheim, M. E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221365 · Cited by 48
Brain myoinositol as a potential marker of amyloid-related pathology
Voevodskaya, O., Poulakis, K., Sundgren, P. C., van Westen, D., Palmqvist, S., Wahlund, L., Stomrud, E., Hansson, O., Westman, E., for the Swedish BioFINDER Study Group, et al. (2019) · Neurology · doi:10.1212/wnl.0000000000006852 · Cited by 49
Self-citationAmyloid PET imaging in clinical practice
Kolanko, M., Win, Z., Loreto, F., Patel, N., Carswell, C. J., Gontsarova, A., Perry, R. J., & Malhotra, P. (2020) · Practical Neurology · doi:10.1136/practneurol-2019-002468 · Cited by 47
Arnerić, S. P., Batrla‐Utermann, R., Beckett, L. A., Bittner, T., Blennow, K., Carter, L., Dean, R. A., Engelborghs, S., Genius, J., Gordon, M. F., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160573 · Cited by 44
Self-citationShaw, L. M. J., Hansson, O., Manuilova, E., Masters, C. L., Doecke, J. D., Li, Q.-X., Rutz, S., Widmann, M., Leinenbach, A., & Blennow, K. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.05.006 · Cited by 44
Self-citationSvärd, D., Nilsson, M., Lampinen, B., Lätt, J., Sundgren, P. C., Stomrud, E., Minthon, L., Hansson, O., & van Westen, D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185239 · Cited by 45
Self-citationTimmers, M., Tesseur, I. C., Bogert, J., Zetterberg, H., Blennow, K., Börjesson‐Hanson, A., Baquero, M., Boada, M., RANDOLPH, C. C., Tritsmans, L., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.03.016 · Cited by 43
Self-citationCerebrospinal fluid biomarkers for Alzheimerʼs disease
Zetterberg, H. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000179 · Cited by 42
Self-citationCardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD
Schultz, S. A., Boots, E. A., Darst, B. F., Zetterberg, H., Blennow, K., Edwards, D. F., Koscik, R. L., Carlsson, C. M., Gallagher, C. L., Bendlin, B. B., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003862 · Cited by 41
Self-citationSala‐Llonch, R., Idland, A., Borza, T., Watne, L. O., Wyller, T. B., Brækhus, A., Zetterberg, H., Blennow, K., Walhovd, K. B., & Fjell, A. M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161146 · Cited by 45
Self-citationAyton, S., Janelidze, S., Roberts, B. R., Palmqvist, S., Kalinowski, P., Diouf, I., Belaidi, A. A., Stomrud, E., Bush, A. I., & Hansson, O. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101904 · Cited by 43
Self-citationSala, A., Nordberg, A. K., Rodriguez‐Vieitez, E., & Initiative, A. D. N. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00950-w · Cited by 43
Association Between Dietary Habits in Midlife With Dementia Incidence Over a 20-Year Period
Glans, I., Sonestedt, E., Nägga, K., Gustavsson, A.-M., González-Padilla, E., Borne, Y., Stomrud, E., Melander, O., Nilsson, P. M., Palmqvist, S., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000201336 · Cited by 40
Self-citationHirota, Y., Sakakibara, Y., Ibaraki, K., Takei, K., Iijima, K., & Sekiya, M. (2022) · Brain Communications · doi:10.1093/braincomms/fcac286 · Cited by 41
Tangen, G. G., Nilsson, M. H., Stomrud, E., Palmqvist, S., & Hansson, O. (2022) · Neurology · doi:10.1212/wnl.0000000000201106 · Cited by 39
Self-citationCan insulin signaling pathways be targeted to transport Aβ out of the brain?
Vandal, M., Bourassa, P., & Calon, F. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00114 · Cited by 37
Bäckström, D. C., Granåsen, G., Mo, S. J., Riklund, K., Trupp, M., Zetterberg, H., Blennow, K., Forsgren, L., & Domellöf, M. E. (2022) · Brain Communications · doi:10.1093/braincomms/fcac040 · Cited by 42
Self-citationCarandini, T., Arighi, A., Sacchi, L., Fumagalli, G. G., Pietroboni, A. M., Ghezzi, L., Colombi, A., Scarioni, M., Fenoglio, C., De Riz, M. A., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0543-7 · Cited by 36
ASC specks as a single-molecule fluid biomarker of inflammation in neurodegenerative diseases
Lobanova, E., Zhang, Y. P., Emin, D., Brelstaff, J., Kahanawita, L., Malpetti, M., Quaegebeur, A., Triantafilou, K., Triantafilou, M., Zetterberg, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53547-0 · Cited by 41
Self-citationPan, C., Korff, A., Galasko, D. R., Ginghină, C., Peskind, E. R., Li, G., Quinn, J. F., Montine, T. J., Cain, K. C., Shi, M. Y., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143099 · Cited by 36
Caldwell, J., Cummings, J. L., Banks, S. J., Palmqvist, S., & Hansson, O. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0565-1 · Cited by 38
Self-citationLaforce, R. J., Rosa‐Neto, P., Soucy, J., Rabinovici, G. D., Dubois, B., & Gauthier, S. G. (2016) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2015.401 · Cited by 34
Lindberg, O. E., Mårtensson, G., Stomrud, E., Palmqvist, S., Wahlund, L., Westman, E., & Hansson, O. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00306 · Cited by 36
Self-citationCSF and blood Kallikrein-8: a promising early biomarker for Alzheimer’s disease
Teuber‐Hanselmann, S., Rekowski, J., Vogelgsang, J. S., Arnim, C. A. F. V., Reetz, K., Stang, A., Jöckel, K., Wiltfang, J., Esselmann, H., Otto, M., et al. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321073 · Cited by 36
Rubinski, A., Franzmeier, N., Dewenter, A., Luan, Y., Smith, R. A., Strandberg, O. T., Ossenkoppele, R., Dichgans, M., Hansson, O., Ewers, M., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01074-9 · Cited by 41
Self-citationPlasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease
Mengel, D., Janelidze, S., Glynn, R. J., Liu, W., Hansson, O., & Walsh, D. M. (2020) · Annals of Neurology · doi:10.1002/ana.25885 · Cited by 32
Self-citationFour subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
ADNI, Duits, F. H., Wesenhagen, K. E. J., Ekblad, L. L., Wolters, E. E., Willemse, E. A. J., Scheltens, P., van der Flier, W. M., Teunissen, C. E., Visser, P. J., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00713-3 · Cited by 34
A 19-Year-Old Adolescent with Probable Alzheimer’s Disease1
Jia, J., Zhang, Y., Shi, Y., Yin, X., Wang, S., Li, Y., Zhao, T., Liu, W., Zhou, A., & Jia, L. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-221065 · Cited by 37
Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease
Prell, T., Witte, O. W., & Großkreutz, J. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00195 · Cited by 32
Reith, F. H., Koran, M. E. I., Davidzon, G., & Zaharchuk, G. (2020) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6573 · Cited by 31
Pereira, J. B., Strandberg, T. O., Palmqvist, S., Volpe, G., van Westen, D., Westman, E., Hansson, O., & Initiative, A. D. N. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx294 · Cited by 33
Self-citationTravassos, M., Santana, I. J., Baldeiras, I., Tsolaki, M., Gkatzima, O., Genç, Ş., Yener, G., Simonsen, A. H., Hasselbalch, S. G., Kapaki, E. N., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150374 · Cited by 32
Self-citationJiang, Y., Huang, H., Abner, E. L., Broster, L. S., Jicha, G. A., Schmitt, F. A., Kryscio, R. J., Andersen, A. H., Powell, D. K., Eldik, L. J. V., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00015 · Cited by 32
Doecke, J. D., Rembach, A., Villemagne, V. L., Varghese, S., Rainey‐Smith, S. R., Sarros, S., Evered, L. A., Fowler, C. J., Pertile, K. K., Rumble, R. L., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170128 · Cited by 32
Bouter, C., Vogelgsang, J. S., & Wiltfang, J. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.02.005 · Cited by 32
CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
Ahmad, S., Milan, M. D. C., Hansson, O., Demirkan, A., Agustin, R., Sáez, M. E., Giagtzoglou, N., Cabrera-Socorro, A., Bakker, M. H. M., Ramirez, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65038-5 · Cited by 31
Self-citationKoychev, I. G., Galna, B., Zetterberg, H., Lawson, J., Zamboni, G., Ridha, B. H., Rowe, J. B., Thomas, A. J., Howard, R. J., Malhotra, P., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180622 · Cited by 30
Self-citationAD biomarker discovery in CSF and in alternative matrices
Sancesario, G. M., & Bernardini, S. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.08.008 · Cited by 30
Binding of Human Proteins to Amyloid-β Protofibrils
Rahman, M. M., Zetterberg, H., Lendel, C., & Härd, T. (2014) · ACS Chemical Biology · doi:10.1021/cb5008663 · Cited by 31
Self-citationHagberg, G., Ihle‐Hansen, H., Fure, B., Thommessen, B., Ihle‐Hansen, H., Øksengård, A. R., Beyer, M. K., Wyller, T. B., Müller, E. G., Pendlebury, S. T., et al. (2020) · BMC Neurology · doi:10.1186/s12883-020-01753-w · Cited by 30
The blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases
Barro, C., & Zetterberg, H. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109281 · Cited by 30
Self-citation
Metadata
- Authors
- Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., & Hansson, O.
- Affiliations
- Lund University (SE)
- University of Gothenburg (SE)
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg and Mölndal, Sweden
- Aarhus University (DK)
- GE Healthcare, Life Sciences, Uppsala, Sweden
- Skåne University Hospital (SE)
- Corresponding author
- Hansson, Oskar
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2014-10-01
- Volume
- 71
- Issue
- 10
- Pages
- 1282
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W1992165389
- Cited by
- 368
- References
- 48
- Citations by year
- 2026: 5 · 2025: 25 · 2024: 21 · 2023: 16 · 2022: 27 · 2021: 38 · 2020: 48 · 2019: 46 · 2018: 31 · 2017: 34 · 2016: 33 · 2015: 39 · 2014: 3
- FWCI
- 27.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA Neurology (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, cortical amyloid deposition, 18F-flutemetamol PET, total tau, phosphorylated tau, diagnostic accuracy, mild cognitive impairment, APOE genotype, hippocampal volume, memory clinics, early detection of neurodegeneration
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Brain, Cerebral Cortex, Cross-Sectional Studies, Female, Gyrus Cinguli, Humans, Male, Middle Aged, Peptide Fragments, Reproducibility of Results, Cohort Studies, Amyloid beta-Peptides, Radiopharmaceuticals, Early Diagnosis, Positron-Emission Tomography, Benzothiazoles, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
